학술논문

Glucose Rate-of-Change and Insulin-on-Board Jointly Weighted Zone Model Predictive Control
Document Type
Periodical
Source
IEEE Transactions on Control Systems Technology IEEE Trans. Contr. Syst. Technol. Control Systems Technology, IEEE Transactions on. 31(5):2261-2274 Sep, 2023
Subject
Signal Processing and Analysis
Communication, Networking and Broadcast Technologies
Computing and Processing
Robotics and Control Systems
Glucose
Insulin
Trajectory
Plasmas
Resistance
Regulation
Predictive control
Adaptive algorithms
closed-loop insulin delivery
diabetes
medical control systems
model predictive control (MPC)
Language
ISSN
1063-6536
1558-0865
2374-0159
Abstract
We present the design and evaluation of closed-loop insulin delivery using zone model predictive control (MPC) featuring an adaptive weighting scheme to address prolonged hyperglycemia due to changes in insulin sensitivity, underdelivery from profile mismatch, and meal composition. In the MPC cost function, the penalty on predicted glucose deviation from the upper zone boundary is weighted by a joint function of predicted glucose rate-of-change (ROC) and insulin-on-board (IOB). The asymmetric weighting gradually increases when glucose ROC and IOB are jointly low, independent of glucose magnitude, to limit hyperglycemia, while aggressively reducing for negative glucose ROC to avoid hypoglycemia. The proposed controller was evaluated using two simulation scenarios: an induced resistance scenario and a nominal scenario to highlight the performance over a reference zone MPC with glucose ROC weighting only. The continuous adaption scheme resulted in consistent improvement for the entire glucose range without incurring an additional risk of hypoglycemia. For the induced resistance and no feedforward bolus scenario, the percent time in 70–180 mg/dL was higher (53.5% versus 48.9%, $p < 0.001$ ) with a larger improvement in the overnight percent time in the tighter glucose range 70–140 mg/dL (70.9% versus 52.9%, $p < 0.001$ ). The results from extensive simulations, as well as clinical validation in three different outpatient studies, demonstrate the utility and safety of the proposed zone MPC.